Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00340132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 299 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    Re-verified, no change to tracked fields

  2. Minor

    Re-verified, no change to tracked fields

  3. Minor

    Eligibility criteria expanded, about 7 words

    Study description revised; Publications: details revised at 17 of 17 entries

    Show what changed: Eligibility criteria
    * INCLUSION CRITERIA: Subjects from all racial and ethnic backgrounds will be invited to participate if they are: * Ages: 18-55 years old (up to 2200 participants) * Gender: male or female EXCLUSION CRITERIA: Subjects will be excluded who are: * Taking medication for a chronic illness. * Have any acute or chronic diseases or conditions not specifi [...] e safety for participation will be considered exclusionary. * Women who currently pregnant or breastfeeding. * Positive for drug and/or nicotine use. All medications and a [...]
    Show what changed: Study description
    [...] nants of insulin resistance and impaired insulin secretion. <TAB>\ Volunteers for this study will be admitted to the clinical [...]
  4. Minor

    10 amendments

    10 re-verifications since 2026-04-30, no change to tracked fields

    v287-v296

  5. Minor

    Site details revised

    Study Status, Contacts/Locationsv286

  6. Minor

    36 amendments

    36 re-verifications since 2024-08-17, no change to tracked fields

    v250-v285

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Insulin resistance and a defect in early insulin secretion are risk factors for the development of type 2 diabetes mellitus. A recent longitudinal analysis which tracked the development of diabetes demonstrated that both insulin action and early insulin secretion deteriorate as individuals progress from normal to impaired glucose tolerance and then to diabetes. These results suggest that both inherent (apparent in normal glucose tolerant subjects who progress to diabetes and likely to have a genetic basis) and acquired (evident as individuals progress from NGT to IGT to diabetes and possibly environmental in origin) defects in insulin action and secretion contribute to the pathogenesis of type 2 diabetes. To identify the genetic and environmental determinants of diabetes we are continuing to determine: (1) if there are genes that segregate with metabolic risk factors for diabetes which might therefore be genetic markers for type 2 diabetes and (2) the mechanisms mediating genetic and environmental determinants of insulin resistance and impaired insulin secretion. \<TAB\> Volunteers for this study will be admitted to the clinical research ward where they will undergo several tests to determine body composition, oral and intravenous glucose tolerance and in vivo insulin action. In addition, in selected subjects, adipose and/or skeletal muscle tissue will be obtained by percutaneous biopsy for in vitro studies of gene expression and insulin action in these tissues. A transformed lymphocyte cell line will be established for each subject as a permanent source of DNA for genetic studies. Genetic markers for type 2 diabetes and insulin resistance will be sought by typing each individual at positional and functional candidate loci in the hopes of finding an association between these loci and obesity, insulin secretion, insulin resistance and/or type 2 diabetes.
Trial Details
NCT Number NCT00340132
Lead Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Enrollment 1,759 participants
Start Date
Updated on ClinicalTrials.gov